Loading clinical trials...

Critical Treatment of Coronary Artery Disease | Clinical Trials | Clareo Health

COMPLETEDNA

Critical Treatment of Coronary Artery Disease

Treatment Strategy for Critical Lesions of Coronary Artery Disease

NCT03195621•Southeast University, China

Summary

Identifying the critical lesion of coronary artery disease and determining the interventional plan are significant for reducing adverse cardiovascular adverse events. The assessment of critical lesion requires the consideration of plaque morphology, tissue composition, and endometrial stress which leading to rupture. In summary, accurate assessment of critical lesions has high application value. In this study, patients with critical coronary artery disease were divided into two groups: an accurate assessment group and a simple assessment group, with the aim to compare the diagnosis and treatment efficiency as well as prognosis, potential cardiovascular risk, possible "excessive" intervention.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Volunteered to participate in this study and signed an informed consent form;
•Men or non-pregnant women ≥ 18 and ≤80 years of age;
•Lesion is located in a coronary artery and stenosis is between 50-75%;

Exclusion Criteria

•Severe liver and kidney diseases (GFR\<60 ml/min/1.73m2 or CTP≥6 score);
•Moderate to severe hypertension (after standard antihypertensive therapy, blood pressure higher than 160/100mmHg);
•Patients with hemodynamic or electrical instability (including shock);
•Coagulation disorders associated with significant bleeding tendency (eg, hypersensitivity, active bleeding, moderate or severe liver disease, GI bleed within the past 6 months, major surgery within 30 days);
•Patients with ischemic stroke within one week;
•Any contraindication against the use of anti-platelet drugs such as aspirin;
•Platelet count less than 100 x 109/L, haemoglobin (Hb) level less than 100 g/L;
•Researchers involved in the study and / or immediate family members;
•Participation in another investigation drug or device study in the past 30 days before enrollment;
•Involvement in the planning and conduct of the study (applies to staffs at study sites);
+2 more criteria

Locations (1)

Zhongda Hospital

Nanjing, Jiangsu, China

Key Dates

Start Date

July 1, 2016

Primary Completion Date

June 30, 2018

Completion Date

June 30, 2019

Last Updated

April 14, 2023

Enrollment

200

ACTUAL participants

Conditions

Coronary Artery DiseaseCoronary Artery Disease Progression

Interventions

Stent implantation

DEVICE

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702

Coronary Artery Disease

View study

RECRUITING

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 14, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Critical Treatment of Coronary Artery Disease

Inclusion Criteria

Exclusion Criteria

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

"Erectile Function After PCI in MI and Non-MI Patients"

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

Product Surveillance Registry

Essential Pro Study ( rEPIC04E-HK )

Factors Affect Outcomes in Cardiovascular Surgery